Unity Long Term Debt vs Capital Surpluse Analysis

UBX Stock

USD 1.24 0.03 2.48%

Unity Biotechnology financial indicator trend analysis is much more than just breaking down Unity Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unity Biotechnology is a good investment. Please check the relationship between Unity Biotechnology Long Term Debt and its Capital Surpluse accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Long Term Debt vs Capital Surpluse

Long Term Debt vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unity Biotechnology Long Term Debt account and Capital Surpluse. At this time, the significance of the direction appears to have pay attention.

The correlation between Unity Biotechnology's Long Term Debt and Capital Surpluse is -0.78. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Unity Biotechnology, assuming nothing else is changed. The correlation between historical values of Unity Biotechnology's Long Term Debt and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Unity Biotechnology are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Long Term Debt i.e., Unity Biotechnology's Long Term Debt and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Unity Biotechnology has held for over one year. Long-term debt appears on Unity Biotechnology balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Unity Biotechnology balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Capital Surpluse

Most indicators from Unity Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unity Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.At this time, Unity Biotechnology's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 83.88 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 4.9 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	61.4M	57.8M	44.7M	67.0M
Cost Of Revenue	2.9M	2.2M	19.7M	14.1M

Total Operating Expenses Cost Of Revenue

Unity Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Total Assets		0.89	0.72	0.78	0.29	0.7	0.4	0.42	-0.17	0.83	-0.47	0.46	0.63	0.63	0.87	0.79	-0.06	-0.5	0.29	-0.06	0.28	-0.46	0.13	0.34	0.86	0.65
Other Current Liab	0.89		0.81	0.91	0.43	0.81	0.44	0.52	-0.35	0.98	-0.64	0.46	0.73	0.74	0.76	0.83	0.18	-0.76	0.48	-0.39	0.47	-0.73	0.34	0.6	0.74	0.8
Total Current Liabilities	0.72	0.81		0.85	-0.02	0.84	0.79	0.84	-0.76	0.73	-0.82	0.73	0.22	0.45	0.43	0.52	0.56	-0.81	0.81	-0.49	0.81	-0.77	0.74	0.76	0.4	0.74
Total Stockholder Equity	0.78	0.91	0.85		0.17	0.78	0.56	0.75	-0.52	0.9	-0.88	0.57	0.53	0.54	0.58	0.78	0.34	-0.93	0.59	-0.55	0.64	-0.91	0.5	0.81	0.55	0.76
Other Liab	0.29	0.43	-0.02	0.17		0.07	-0.36	-0.41	0.41	0.53	0.22	-0.32	0.61	0.76	0.49	0.46	-0.41	-0.02	-0.32	-0.09	-0.27	-0.02	-0.31	-0.17	0.5	0.09
Net Tangible Assets	0.7	0.81	0.84	0.78	0.07		0.63	0.67	-0.7	0.77	-0.68	0.59	0.5	0.48	0.48	0.57	0.59	-0.71	0.81	-0.33	0.7	-0.67	0.62	0.73	0.46	0.67
Property Plant And Equipment Net	0.4	0.44	0.79	0.56	-0.36	0.63		0.9	-0.87	0.32	-0.72	0.97	-0.06	0.26	-0.08	0.35	0.64	-0.59	0.84	-0.12	0.91	-0.55	0.83	0.73	-0.1	0.7
Net Debt	0.42	0.52	0.84	0.75	-0.41	0.67	0.9		-0.88	0.45	-0.94	0.87	0.0	0.15	0.02	0.41	0.71	-0.83	0.86	-0.42	0.92	-0.81	0.82	0.9	-0.01	0.67
Retained Earnings	-0.17	-0.35	-0.76	-0.52	0.41	-0.7	-0.87	-0.88		-0.29	0.77	-0.77	0.13	-0.07	0.2	-0.13	-0.92	0.68	-0.98	0.43	-0.96	0.66	-0.93	-0.83	0.23	-0.53
Accounts Payable	0.83	0.98	0.73	0.9	0.53	0.77	0.32	0.45	-0.29		-0.62	0.35	0.77	0.77	0.75	0.84	0.17	-0.76	0.42	-0.44	0.41	-0.74	0.26	0.58	0.73	0.72
Cash	-0.47	-0.64	-0.82	-0.88	0.22	-0.68	-0.72	-0.94	0.77	-0.62		-0.71	-0.17	-0.24	-0.16	-0.53	-0.64	0.96	-0.78	0.61	-0.84	0.95	-0.71	-0.94	-0.13	-0.67
Non Current Assets Total	0.46	0.46	0.73	0.57	-0.32	0.59	0.97	0.87	-0.77	0.35	-0.71		0.05	0.35	-0.03	0.49	0.55	-0.57	0.75	0.01	0.84	-0.54	0.69	0.69	-0.05	0.73
Non Currrent Assets Other	0.63	0.73	0.22	0.53	0.61	0.5	-0.06	0.0	0.13	0.77	-0.17	0.05		0.69	0.68	0.77	-0.16	-0.34	0.03	-0.01	-0.04	-0.35	-0.18	0.21	0.68	0.56
Other Assets	0.63	0.74	0.45	0.54	0.76	0.48	0.26	0.15	-0.07	0.77	-0.24	0.35	0.69		0.51	0.83	-0.06	-0.38	0.16	0.0	0.24	-0.35	0.07	0.26	0.51	0.57
Cash And Short Term Investments	0.87	0.76	0.43	0.58	0.49	0.48	-0.08	0.02	0.2	0.75	-0.16	-0.03	0.68	0.51		0.61	-0.32	-0.28	-0.05	-0.11	-0.13	-0.25	-0.22	0.03	1.0	0.35
Common Stock Total Equity	0.79	0.83	0.52	0.78	0.46	0.57	0.35	0.41	-0.13	0.84	-0.53	0.49	0.77	0.83	0.61		-0.02	-0.59	0.22	-0.03	0.31	-0.57	0.06	0.48	0.6	0.66
Common Stock Shares Outstanding	-0.06	0.18	0.56	0.34	-0.41	0.59	0.64	0.71	-0.92	0.17	-0.64	0.55	-0.16	-0.06	-0.32	-0.02		-0.58	0.91	-0.45	0.81	-0.58	0.79	0.73	-0.35	0.33
Non Current Liabilities Total	-0.5	-0.76	-0.81	-0.93	-0.02	-0.71	-0.59	-0.83	0.68	-0.76	0.96	-0.57	-0.34	-0.38	-0.28	-0.59	-0.58		-0.72	0.73	-0.77	1.0	-0.66	-0.93	-0.25	-0.71
Capital Surpluse	0.29	0.48	0.81	0.59	-0.32	0.81	0.84	0.86	-0.98	0.42	-0.78	0.75	0.03	0.16	-0.05	0.22	0.91	-0.72		-0.44	0.93	-0.7	0.9	0.84	-0.07	0.62
Other Current Assets	-0.06	-0.39	-0.49	-0.55	-0.09	-0.33	-0.12	-0.42	0.43	-0.44	0.61	0.01	-0.01	0.0	-0.11	-0.03	-0.45	0.73	-0.44		-0.45	0.74	-0.52	-0.61	-0.08	-0.23
Other Stockholder Equity	0.28	0.47	0.81	0.64	-0.27	0.7	0.91	0.92	-0.96	0.41	-0.84	0.84	-0.04	0.24	-0.13	0.31	0.81	-0.77	0.93	-0.45		-0.74	0.95	0.9	-0.16	0.63
Total Liab	-0.46	-0.73	-0.77	-0.91	-0.02	-0.67	-0.55	-0.81	0.66	-0.74	0.95	-0.54	-0.35	-0.35	-0.25	-0.57	-0.58	1.0	-0.7	0.74	-0.74		-0.63	-0.92	-0.22	-0.69
Property Plant And Equipment Gross	0.13	0.34	0.74	0.5	-0.31	0.62	0.83	0.82	-0.93	0.26	-0.71	0.69	-0.18	0.07	-0.22	0.06	0.79	-0.66	0.9	-0.52	0.95	-0.63		0.81	-0.25	0.54
Preferred Stock Total Equity	0.34	0.6	0.76	0.81	-0.17	0.73	0.73	0.9	-0.83	0.58	-0.94	0.69	0.21	0.26	0.03	0.48	0.73	-0.93	0.84	-0.61	0.9	-0.92	0.81		0.0	0.66
Total Current Assets	0.86	0.74	0.4	0.55	0.5	0.46	-0.1	-0.01	0.23	0.73	-0.13	-0.05	0.68	0.51	1.0	0.6	-0.35	-0.25	-0.07	-0.08	-0.16	-0.22	-0.25	0.0		0.33
Common Stock	0.65	0.8	0.74	0.76	0.09	0.67	0.7	0.67	-0.53	0.72	-0.67	0.73	0.56	0.57	0.35	0.66	0.33	-0.71	0.62	-0.23	0.63	-0.69	0.54	0.66	0.33

Click cells to compare fundamentals

Unity Biotechnology Account Relationship Matchups

Unity Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	151.2M	156.3M	124.7M	124.4M	65.7M	100.2M
Other Current Liab	12.0M	7.4M	7.0M	5.3M	3.0M	5.5M
Total Current Liabilities	17.2M	14.5M	16.6M	19.6M	7.8M	14.3M
Total Stockholder Equity	120.7M	82.9M	59.6M	66.8M	28.4M	27.0M
Other Liab	3.3M	4.1M	13.3M	23K	26.5K	25.1K
Net Tangible Assets	120.7M	82.9M	59.6M	66.8M	76.9M	57.5M
Property Plant And Equipment Net	16.6M	36.1M	31.2M	26.9M	18.1M	19.9M
Net Debt	(37.4M)	41.2M	18.7M	34.6M	7.2M	7.5M
Retained Earnings	(245.5M)	(339.3M)	(400.0M)	(460.0M)	(484.4M)	(460.1M)
Accounts Payable	5.2M	2.6M	2.0M	1.8M	1.4M	2.1M
Cash	37.5M	17.8M	32.9M	12.7M	19.8M	23.3M
Non Current Assets Total	21.7M	55.5M	34.2M	27.8M	19.1M	25.2M
Non Currrent Assets Other	2.1M	1.4M	987K	52K	1.0M	981.1K
Other Assets	2.1M	1.4M	987K	948K	853.2K	992.6K
Cash And Short Term Investments	127.5M	97.7M	88.1M	94.8M	43.2M	79.8M
Common Stock Shares Outstanding	4.4M	5.1M	5.6M	9.5M	14.8M	15.5M
Short Term Investments	90.0M	79.9M	55.2M	82.1M	23.4M	22.2M
Liabilities And Stockholders Equity	151.2M	156.3M	124.7M	124.4M	65.7M	100.2M
Non Current Liabilities Total	13.3M	59.0M	48.5M	37.9M	29.5M	33.0M
Capital Surpluse	324.7M	366.7M	422.4M	527.0M	606.1M	636.4M
Other Current Assets	2.0M	6.3M	2.4M	1.5M	1.8M	2.1M
Other Stockholder Equity	366.1M	422.2M	459.6M	500.8M	512.8M	355.1M
Total Liab	30.5M	73.4M	65.1M	57.5M	37.3M	43.4M
Property Plant And Equipment Gross	16.6M	12.6M	31.2M	26.9M	27.3M	17.9M
Total Current Assets	129.5M	100.9M	90.5M	96.5M	46.6M	81.9M
Accumulated Other Comprehensive Income	90K	5K	(44K)	(251K)	(24K)	(25.2K)
Common Stock	3K	4K	5K	6K	2K	3.7K
Property Plant Equipment	16.6M	36.1M	31.2M	7.8M	9.0M	16.9M
Net Invested Capital	120.7M	107.4M	81.0M	87.2M	28.4M	27.0M
Net Working Capital	112.3M	86.4M	73.9M	76.9M	38.8M	71.5M
Short Long Term Debt Total	45K	59.0M	51.6M	47.4M	27.0M	33.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unity Long Term Debt vs Capital Surpluse Analysis

Long Term Debt vs Capital Surpluse

Long Term Debt vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Long Term Debt

Capital Surpluse

Unity Biotechnology fundamental ratios Correlations

Unity Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unity Biotechnology fundamental ratios Accounts

Also Currently Popular

Additional Tools for Unity Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Accounts Payable	+ 0.98	Other Current Liab
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Non Current Liabilities Total	+ 0.96	Cash
Total Liab	+ 0.95	Cash

Capital Surpluse	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Preferred Stock Total Equity	- 0.94	Cash
Cash	- 0.94	Net Debt
Preferred Stock Total Equity	- 0.93	Non Current Liabilities Total
Property Plant And Equipment Gross	- 0.93	Retained Earnings